Upadacitinib, a selective JAK1/3 inhibitor for the treatment of severe RA, inhibits IL‐6, GM‐CSF, and IFN‐γ production and has anti‐inflammatory potential for COVID‐19, and currently has one clinical trial registration (NCT04393311).276, 277. This evidence concerns the gene CSF2 and rheumatoid arthritis.